Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
P-269 Phase II trial of Irinotecan/S-1 (IRIS) with Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS WT metastatic colorectal cancer: HGCSG0902. -Comparison of administration interval in Cetuximab treatment
Kazuteru Hatanaka, Satoshi Yuki, Hiroshi Nakatsumi, A. Hosokawa, Michio Nakamura, Osamu Muto, T. Meguro, Ichiro Iwanaga, Yasushi Tsuji, Akinori Sato, K. Eto, Koichi Furukawa, Makoto Onodera, M. Tateyama, Yasuo Takahashi, Masayoshi Dazai, Shigeyuki Yokoyama, Takuya Honda, Hiroyuki Okuda, Masatoshi Kudo, Yuh Sakata, Yoshito Komatsu (2015). P-269 Phase II trial of Irinotecan/S-1 (IRIS) with Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS WT metastatic colorectal cancer: HGCSG0902. -Comparison of administration interval in Cetuximab treatment. , 26, DOI: https://doi.org/10.1093/annonc/mdv233.266.
Article40 days ago162P Updated analysis: Phase II trial of irinotecan plus S-1 (IRIS) with cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type metastatic colorectal cancer (mCRC): HGCSG0902
A. Hosokawa, Satoshi Yuki, Yasuyuki Kawamoto, Takayuki Ando, Osamu Muto, Michio Nakamura, Takashi Kato, Ichiro Iwanaga, Kazuteru Hatanaka, Yasushi Tsuji, Akinori Sato, K. Eto, Kouichi Furukawa, Hiroyuki Okuda, Hideo Hayashi, Kei Fujikawa, Masatoshi Kudo, Takuya Honda, Yuh Sakata, Yoshito Komatsu (2015). 162P Updated analysis: Phase II trial of irinotecan plus S-1 (IRIS) with cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type metastatic colorectal cancer (mCRC): HGCSG0902. , 26, DOI: https://doi.org/10.1093/annonc/mdv523.23.
Article40 days ago172P Updated analysis: observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin (OX) + BV and oral FU/OX + BV
Yoshito Komatsu, Satoshi Yuki, Hiroshi Nakatsumi, Kentaro Sawada, Kazuteru Hatanaka, Takashi Kato, T. Meguro, Michio Nakamura, Ichiro Iwanaga, Minoru Uebayashi, M. Tateyama, K. Eto, Masatoshi Kudo, K. Kato, Hiroyuki Okuda, Susumu Sogabe, T. Miyagishima, Kencho Miyashita, Naoya Sakamoto, Yuh Sakata (2015). 172P Updated analysis: observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin (OX) + BV and oral FU/OX + BV. , 26, DOI: https://doi.org/10.1093/annonc/mdv523.33.
Article40 days ago157P Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type mCRC: Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP/HGCSG1001: updated analysis of anti-tumor efficacy
Satoshi Yuki, Yoshito Komatsu, Hiroshi Nakatsumi, Toshiya Muranaka, Y. Kobayashi, T. Miyagishima, Nobuyuki Ehira, Ichiro Iwanaga, Hiroyuki Okuda, M. Tateyama, Yasushi Tsuji, Kazuteru Hatanaka, Michio Nakamura, Masatoshi Kudo, H. Fukushima, Hiroyuki Hisai, Riichiro Abe, Naoya Sakamoto, Koji Oba, Yuh Sakata (2015). 157P Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type mCRC: Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP/HGCSG1001: updated analysis of anti-tumor efficacy. , 26, DOI: https://doi.org/10.1093/annonc/mdv523.18.
Article40 days agoFirst Report of a Phase Ii Trial of Irinotecan Plus S-1 (Iris) with Cetuximab (Iris/Cet) in Pre-Treated Patients with Kras Wild Type of Metastatic Colorectal Cancer (Mcrc): Hgcsg0902
Osamu Muto, Satoshi Yuki, Michio Nakamura, A. Hosokawa, Takashi Kato, Ichiro Iwanaga, Kazuteru Hatanaka, Yasushi Tsuji, Akinori Sato, K. Eto, Koichi Furukawa, Hiroyuki Okuda, Makoto Onodera, Kei Fujikawa, Masatoshi Kudo, Shigeyuki Yokoyama, Takuya Honda, Yuh Sakata, Yoshito Komatsu (2014). First Report of a Phase Ii Trial of Irinotecan Plus S-1 (Iris) with Cetuximab (Iris/Cet) in Pre-Treated Patients with Kras Wild Type of Metastatic Colorectal Cancer (Mcrc): Hgcsg0902. , 25, DOI: https://doi.org/10.1093/annonc/mdu333.41.
Article40 days ago